TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30321520

Group type: EXPERIMENTAL
Intervention: IV ibuprofen (800 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: IV acetaminophen (1000 mg)
Number of subjects: 58
Study: 27344987

Group type: EXPERIMENTAL
Intervention: Compounded dexamethasone mouth rinse
Number of subjects: 9

Group type: COMPARATOR
Intervention: Existing therapy (self-formulated dexamethasone mouth rinse)
Number of subjects: 9
Study: 25660225

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS‐TBNA)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional diagnosis and staging (CDS)
Number of subjects: 133
Study: 23302603

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 2312

Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure (BP)
Number of subjects: 2312

Group type: EXPERIMENTAL
Intervention: Total cholesterol level
Number of subjects: 2312
Study: 21272091

Group type: EXPERIMENTAL
Intervention: Silodosin at 4 mg twice a day
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tamsulosin at 0.2 mg once a day
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Naftopidil at 50 mg once a day
Number of subjects: 136
Study: 19541816

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 2102
Study: 16772812

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/d
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group without amantadine
Number of subjects: 14
Study: 15585759

Group type: EXPERIMENTAL
Intervention: Butter meal (38% SFAs, 22% MUFAs, 4% PUFAs, and 0.7% alpha‐linolenic acid)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Walnut meal (20% SFAs, 24% MUFAs, 16% PUFAs, and 4% alpha‐linolenic acid)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Olive oil meal (22% SFAs, 38% MUFAs, 4% PUFAs, and 0.7% alpha‐linolenic acid)
Number of subjects: 8

Group type: COMPARATOR
Intervention: All meals (olive oil, butter, walnut)
Number of subjects: 8
Study: 12905865

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 89

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 89
Study: 9131756

Group type: EXPERIMENTAL
Intervention: Blinded subjective rankings
Number of subjects: 0
Study: 8361890

Group type: EXPERIMENTAL
Intervention: digoxin, furosemide, nifedipine (N)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: digoxin, furosemide, isosorbide dinitrate (S)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: digoxin, furosemide, isosorbide dinitrate (S) and captopril (K)
Number of subjects: 46
Study: 3499154

Group type: EXPERIMENTAL
Intervention: 2,000 cGy total lymphoid irradiation (TLI)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Herpes zoster occurrence
Number of subjects: 13
Study: 31809827

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study: 29287276

Group type: EXPERIMENTAL
Intervention: Noninvasive measures (e.g., the use of a 'soft room', observation in seclusion)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Invasive measures (e.g., mechanical restraint, forced medication)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Forced medication and mechanical restraint
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Retrospective understanding of coercive measures
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Options for reducing coercion (e.g., music or exercises)
Number of subjects: 264
Study: 26198283

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with diluted epinephrine and 0.5% dexamethasone (LED)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with diluted epinephrine (LE)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 0.9% saline (S)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (C) without BAL
Number of subjects: 240
Study: 25448515

Group type: EXPERIMENTAL
Intervention: 500 mg of intramuscular 17OHP‐C weekly until 36 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 17OHP‐C
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 23346989

Group type: EXPERIMENTAL
Intervention: Self-selected music
Number of subjects: 100

Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 100
Study: 20559296

Group type: COMPARATOR
Intervention: Placebo + BMOD (N = 202)
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 591)
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo + BMOD (N = 193)
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 482)
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo + BMOD (N = 106)
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD (N = 301)
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) + Bupropion SR (360 mg/day) + BMOD
Number of subjects: 793
Study: 18359326

Group type: EXPERIMENTAL
Intervention: Simvastatin and Ezetimibe
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1758
Study: 16553529

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 14606739

Group type: EXPERIMENTAL
Intervention: Aerobic training (eight-week programme using a leg cycle ergometer)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study: 10392861

Group type: EXPERIMENTAL
Intervention: Poloxamer 188 as ancillary therapy to thrombolysis
Number of subjects: 74

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 74
Study: 8707981

Group type: EXPERIMENTAL
Intervention: 0.1% delmopinol mouthwash
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol mouthwash
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 450
Study: 1846784

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/24 hr
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sotalol 640 mg/24 hr
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 10
Study: 6295691

Group type: EXPERIMENTAL
Intervention: 40 mmol sodium intake
Number of subjects: 9

Group type: COMPARATOR
Intervention: 200 mmol sodium intake
Number of subjects: 9
Study: 30625242

Group type: EXPERIMENTAL
Intervention: High-quality, intensive early childhood program
Number of subjects: 0
Study: 29374881

Group type: EXPERIMENTAL
Intervention: Hyperandrogenic PCOS
Number of subjects: 484

Group type: COMPARATOR
Intervention: Normoandrogenic PCOS
Number of subjects: 484
Study: 27401037

Group type: EXPERIMENTAL
Intervention: Ergocalciferol (Group VitD2)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Calcitriol (Group aVitD3)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 204
Study: 23681677

Group type: EXPERIMENTAL
Intervention: Parent-child interaction therapy (immediate treatment)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 28
Study: 22543069

Group type: EXPERIMENTAL
Intervention: Tibial nerve block in the popliteal fossa
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sciatic nerve block combined with femoral nerve block
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tibial nerve block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sciatic nerve block
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tibial nerve block and Sciatic nerve block
Number of subjects: 80
Study: 20166415

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Plus (ASB) - two‐step etch‐and‐rinse
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond SE (AS) - two‐step self‐etch
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE) - two‐step self‐etch
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: XENO V (X) - one‐step self‐etch
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adper Easy Bond (AE) - one‐step self‐etch
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control - high C-factor mold
Number of subjects: 200
Study: 18580176

Group type: EXPERIMENTAL
Intervention: Adaptive-support ventilation (ASV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pressure-regulated volume-controlled ventilation with automode (PRVCa)
Number of subjects: 50
Study: 16821204

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN), 10 mg daily for 2 years
Number of subjects: 19
Study: 11918754

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 9647536

Group type: EXPERIMENTAL
Intervention: Short-acting GnRHa (leuprolide acetate)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Long-acting GnRHa (leuprolide acetate)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Long-acting GnRHa (tryptorelin)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 183
Study: 7734258

Group type: EXPERIMENTAL
Intervention: 51W89 (0.1 mg kg‐1, 2 x ED95)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Atracurium (0.4 mg kg‐1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 51W89
Number of subjects: 32
Study: 2789932

Group type: EXPERIMENTAL
Intervention: Yohimbine (14 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4154818

Group type: EXPERIMENTAL
Intervention: Fluoride topical application twice a year (Group 3)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Fluoride topical application once a year (Group 2)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 497
Study: 29432772

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (L. acidophilus, L. plantarum, L. fermentum, L. gasseri with fructooligosaccharide for 6 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26031995

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise
Number of subjects: 202

Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 202
Study: 24417565

Group type: EXPERIMENTAL
Intervention: Self-administered checklist
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study: 23652044

Group type: EXPERIMENTAL
Intervention: 45 mg/m2 gambogic acid intravenously from Days 1 to 5 of a 2-week cycle (Group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 45 mg/m2 gambogic acid every other day for a total of five times during a 2-week cycle (Group B)
Number of subjects: 47
Study: 21322147

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day) and Fluoxetine (20 mg/day) for 6 months
Number of subjects: 280

Group type: COMPARATOR
Intervention: Naltrexone and Fluoxetine placebo
Number of subjects: 280

Group type: COMPARATOR
Intervention: Naltrexone placebo and Fluoxetine
Number of subjects: 280

Group type: COMPARATOR
Intervention: Naltrexone placebo and Fluoxetine placebo
Number of subjects: 280
Study: 19107262

Group type: EXPERIMENTAL
Intervention: Pulpotomy technique using formocresol as a temporary dressing and zinc oxide-eugenol cement for obturation (group 1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pulpectomy technique with calcium hydroxide paste as a temporary dressing and dense calcium hydroxide paste for obturation (group 2)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both techniques (group 1 and group 2)
Number of subjects: 51
Study: 16871932

Group type: COMPARATOR
Intervention: Topical mitomycin-C (MMC) applied at a concentration of 0.5 mg/mL for 4 minutes post-frontal sinusotomy.
Number of subjects: 0
Study: 14696846

Group type: EXPERIMENTAL
Intervention: Beta-glucuronidase activity in CSF before treatment
Number of subjects: 43
Study: 11154366

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus (ISBP) block
Number of subjects: 40

Group type: COMPARATOR
Intervention: No block (Control)
Number of subjects: 40
Study: 9150588

Group type: EXPERIMENTAL
Intervention: Experiential mode of thinking with mortality salience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rational mode of thinking with mortality salience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiential mode with mortality salience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rational mode with mortality salience
Number of subjects: 0
Study: 7944244

Group type: EXPERIMENTAL
Intervention: Midazolam with nalbuphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study: 3591425

Group type: EXPERIMENTAL
Intervention: Fronto-frontal ECT (FF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temporo-parietal ECT (TP)
Number of subjects: 0
Study: 15235963

Group type: COMPARATOR
Intervention: Continuous epidural infusion of 0.25% bupivacaine at a rate of 2‐5 ml.hr(‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of 0.125% or 0.25% bupivacaine and 0.0025% or 0.005% morphine at a rate of 2‐4 ml.hr(‐1)
Number of subjects: 16
Study: 788570

Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid plus rifampicin
Number of subjects: 673

Group type: COMPARATOR
Intervention: Isoniazid plus rifampicin
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Streptomycin, isoniazid, rifampicin, and pyrazinamide followed by thiacetazone plus isoniazid
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid plus pyrazinamide twice a week
Number of subjects: 673
Study: 31811006

Group type: EXPERIMENTAL
Intervention: Multifaceted eHealth strategy (mobile website, digital newsletters, social media)
Number of subjects: 779

Group type: COMPARATOR
Intervention: Usual care (digital patient information letter)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Multifaceted eHealth strategy
Number of subjects: 779

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 779
Study: 28656713

Group type: EXPERIMENTAL
Intervention: 90:10 deproteinized bovine bone (DPBB) and autogenous bone (AB) mixture
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 60:40 deproteinized bovine bone (DPBB) and autogenous bone (AB) mixture
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both mixtures (90:10 and 60:40)
Number of subjects: 13
Study: 26555123

Group type: EXPERIMENTAL
Intervention: Telephone and mailed outreach individualized based on cardiovascular disease risk and uncontrolled risk factors provided by lay health workers.
Number of subjects: 646

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Not applicable.
Number of subjects: 646
Study: 23216520

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme for 9 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 21252501

Group type: EXPERIMENTAL
Intervention: Intratympanic injection of AM-101
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20137557

Group type: EXPERIMENTAL
Intervention: Medium- and long-chain fatty acid triacylglycerol (MLCT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Long-chain fatty acid triacylglycerol (LCT)
Number of subjects: 101
Study: 17367658

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Aliskiren (all doses)
Number of subjects: 672
Study: 15253102

Group type: COMPARATOR
Intervention: Amlodipine besilate (14 patients)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cilnidipine (14 patients)
Number of subjects: 28
Study: 11454260

Group type: EXPERIMENTAL
Intervention: Autologous fresh platelet concentrate (PC); n = 24
Number of subjects: 48

Group type: COMPARATOR
Intervention: Autologous fresh whole blood (WB); n = 24
Number of subjects: 48
Study: 9789646

Group type: EXPERIMENTAL
Intervention: Administration of antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7811656

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intranasal midazolam
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg intranasal midazolam
Number of subjects: 43
Study: 3379200

Group type: EXPERIMENTAL
Intervention: Frequency analysis with fast Fourier transform and time domain analysis after signal averaging and high gain, low noise amplification (0 to 300 Hz) in patients with ventricular tachycardia.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients without ventricular tachycardia after infarction.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy subjects.
Number of subjects: 60
Study: 31980145

Group type: EXPERIMENTAL
Intervention: FLOT regimen (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel)
Number of subjects: 716

Group type: COMPARATOR
Intervention: ECF/ECX regimen (epirubicin, cisplatin, and 5-fluorouracil or capecitabine)
Number of subjects: 716
Study: 30803175

Group type: EXPERIMENTAL
Intervention: Oral magnesium sulfate solution in split doses (group A, n=178)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Single dose group (group B, n=190)
Number of subjects: 368
Study: 29327733

Group type: EXPERIMENTAL
Intervention: Functional appliance (Modify Monobloc, MM)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Functional therapy of mandibular advancement
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral appliance
Number of subjects: 51

Group type: COMPARATOR
Intervention: Untreated Class II malocclusion
Number of subjects: 51
Study: 25400085

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous hydrocortisone infusion (CSHI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Thrice-daily regimen of oral hydrocortisone (OHC)
Number of subjects: 25
Study: 23702187

Group type: EXPERIMENTAL
Intervention: Night Eating Restriction (NER) for 2 weeks (elimination of energy intake from 19.00 to 06.00 hours)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Night Eating Restriction (NER)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control condition for 2 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 29
Study: 21534679

Group type: EXPERIMENTAL
Intervention: Loss-framed message with fear induction
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Gain-framed message with anger induction
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Matched message frame to emotional state
Number of subjects: 133
Study: 18465720

Group type: EXPERIMENTAL
Intervention: HSM hydrophilic acrylic IOL (BioVue3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL (Sensar)
Number of subjects: 100
Study: 16856905

Group type: EXPERIMENTAL
Intervention: IFN-alpha (3 MU s.c. three times a week for 6 months)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No IFN-alpha (control group)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: IFN-alpha
Number of subjects: 167

Group type: COMPARATOR
Intervention: No IFN-alpha
Number of subjects: 167
Study: 12558913

Group type: COMPARATOR
Intervention: CIFN 9 microg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CIFN 9 microg daily plus ribavirin 1000 or 1200 mg daily
Number of subjects: 40
Study: 10736983

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/die)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/die)
Number of subjects: 53
Study: 8757573

Group type: EXPERIMENTAL
Intervention: Study subjects (intervention group)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Study women (intervention group)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Study men (intervention group)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 209
Study: 1601147

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) - leuprolide acetate (500 micrograms)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Human chorionic gonadotropin (hCG) - 5,000 IU
Number of subjects: 179
Study: 6397871

Group type: EXPERIMENTAL
Intervention: High-dose oral anticoagulation with shorter heparin treatment
Number of subjects: 169

Group type: COMPARATOR
Intervention: Low-dose oral anticoagulation with conventional heparin treatment
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: High-dose oral anticoagulation with shorter heparin treatment (second part of the study)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Low-dose oral anticoagulation with conventional heparin treatment (second part of the study)
Number of subjects: 169
Study: 31144435

Group type: EXPERIMENTAL
Intervention: GLP1RA plus basal insulin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basal-bolus insulin
Number of subjects: 120
Study: 29720084

Group type: EXPERIMENTAL
Intervention: SMART MOVE intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group participants
Number of subjects: 18
Study: 26990766

Group type: EXPERIMENTAL
Intervention: AQW051 10 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: AQW051 50 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 24576194

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SHAM (no WBV)
Number of subjects: 16
Study: 23537728

Group type: EXPERIMENTAL
Intervention: Meat Githeri
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Plain Githeri (githeri+oil)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Milk Githeri
Number of subjects: 902

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 902
Study: 21253451

Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS)
Number of subjects: 247
Study: 17689205

Group type: EXPERIMENTAL
Intervention: Concurrent smoking cessation treatment during alcohol treatment
Number of subjects: 499

Group type: COMPARATOR
Intervention: Delayed smoking cessation treatment (6 months later)
Number of subjects: 499